Table 2.

Mean viral kinetic parameters estimated using a population approach

Model		t0 [day]	ε		δ [day−1]	η	AIC
			10+15 mg/kg/day dosing group	20 mg/kg/day dosing group
Blocking infection only	Pop. parameters	0**	0	0	3.36	0.40*	232.7
	SE				1.30	0.072
	Q1–Q3				2.0–5.81	--
Blocking production only	Pop. parameters	0.68	0.69	0.91	0.91	0	26.3
	SE	0.036	0.13	0.034	0.076
	Q1–Q3	0.65–0.73	0.43–0.81	0.72–0.98	0.78–1.03
Blocking production and infection	Pop. parameters	0.66	0.49	0.89	0.77	0.60*	16.7
	SE	0.11	0.19	0.049	0.075	0.18
	Q1–Q3	0.63–0.70	0.24–0.80	0.66–0.98	0.65–0.90

^*Parameter estimated assuming no inter-individual variations; Pop. parameters, parameters estimated using mixed-effect modeling (see Methods);

^**t₀ was fixed to zero; SE, standard error; Q1–Q3: first and third quartiles of the distribution of the individual a posteriori estimates (see Supp. Materials); t₀, HCV delay before decline begins; ε, SIL effectiveness in blocking viral production/release; δ, HCV-infected cell loss rate; η; SIL effectiveness in blocking viral infection; AIC; Akaike information criterion. The model with the lowest AIC is considered the best.